Nuvelo(NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo(NUVO)

NUVO 0.170

+169,917.0%

Aug 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (112)	12/8/2006 12:54:04 PM
From: Arthur Radley	Read Replies (1) of 140

WASHINGTON, Dec 8 (Reuters) - The U.S. Food and Drug Administration and Baxter International Inc. (BAX.N: Quote, Profile , Research) notified doctors that the drug Heparin could be linked to thrombosis or blood clots in patients several weeks after they stop taking it, the agency said on Friday. The FDA said it revised the warnings section of the prescribing information for Heparin, a blood thinner, because of the possibility of delayed onset of thrombocytopenia and thrombosis. The agency described that as a "serious antibody-mediated reaction resulting from irreversible aggregation of platelets." +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ This "could" be a major positive for NUVO as they are testing rNAPc2 as a replacement drug for Heparin.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next